Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line

Eribulin is a new drug to treat soft tissue sarcoma (STS) that exerts antitumor activity by binding to microtubules. The prognosis of STS is poor, and eribulin is expected to improve the treatment outcome. We observed several cases that exhibited resistance to eribulin and developed an eribulin-resi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Anal Cell Pathol (Amst)
Glavni autori: Yahiro, Kenichiro, Matsumoto, Yoshihiro, Fukushi, Jun-ichi, Kawaguchi, Ken-ichi, Endo, Makoto, Setsu, Nokitaka, IIda, Keiichiro, Fukushima, Suguru, Nakagawa, Makoto, Kimura, Atsushi, Oda, Yoshinao, Nakashima, Yasuharu
Format: Artigo
Jezik:Inglês
Izdano: Hindawi 2018
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033248/
https://ncbi.nlm.nih.gov/pubmed/30034996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/8987568
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items